» Articles » PMID: 16393226

Increased Risk of Intestinal Cancer in Crohn's Disease: a Meta-analysis of Population-based Cohort Studies

Overview
Specialty Gastroenterology
Date 2006 Jan 6
PMID 16393226
Citations 169
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The risk of intestinal malignancy in Crohn's disease (CD) remains uncertain since risk estimates vary worldwide. The global CD population is growing and there is a demand for better knowledge of prognosis of this disease. Hence, the aim of the present study was to conduct a meta-analysis of population-based data on intestinal cancer risk in CD.

Methods: The MEDLINE search engine and abstracts from international conferences were searched for the relevant literature by use of explicit search criteria. All papers fulfilling the strict inclusion criteria were scrutinized for data on population size, time of follow-up, and observed to expected cancer rates. STATA meta-analysis software was used to perform overall pooled risk estimates (standardized incidence ratio (SIR), observed/expected) and meta-regression analyses of the influence of specific variables on SIR.

Results: Six papers fulfilled the inclusion criteria and reported SIRs of colorectal cancer (CRC) in CD varying from 0.9 to 2.2. The pooled SIR for CRC was significantly increased (SIR, 1.9; 95% CI 1.4-2.5), as was the risk for colon cancer separately (SIR, 2.5; 95% CI 1.7-3.5). Regarding small bowel cancer, five studies reported SIRs ranging from 3.4 to 66.7, and the overall pooled estimate was 27.1 (95% CI 14.9-49.2).

Conclusions: The present meta-analysis of intestinal cancer risk in CD, based on population-based studies only, revealed an overall increased risk of both CRC and small bowel cancer among patients with CD. However, some of the available data were several decades old, and future studies taking new treatment strategies into account are required.

Citing Articles

Surgery for Colorectal Cancer Associated with Crohn's Disease-Toward a Medical Treatment Strategy Based on the Differences Between Japan and Western Countries.

Sekido Y, Ogino T, Takeda M, Hata T, Hamabe A, Miyoshi N Cancers (Basel). 2025; 17(5).

PMID: 40075707 PMC: 11899177. DOI: 10.3390/cancers17050860.


Colorectal Cancer: Pathogenesis and Targeted Therapy.

Li J, Pan J, Wang L, Ji G, Dang Y MedComm (2020). 2025; 6(3):e70127.

PMID: 40060193 PMC: 11885891. DOI: 10.1002/mco2.70127.


Clinical Characteristics and Outcomes of Small Bowel Neoplasms in Crohn's Disease: A Case-Control Study.

Urquhart S, Smyrk T, Harmsen W, Loftus Jr E, Kisiel J, Coelho-Prabhu N Crohns Colitis 360. 2025; 7(1):otaf001.

PMID: 39959612 PMC: 11829073. DOI: 10.1093/crocol/otaf001.


Assessment of the Utility of Selected Inflammatory Markers in Correlation with Magnetic Resonance Enterography (MRE) Findings in the Diagnosis of Crohn's Disease.

Lorenc-Gora J, Waniczek D, Czuba Z, Kryj M, Lorenc Z, Muc-Wierzgon M Biomolecules. 2025; 15(1).

PMID: 39858510 PMC: 11763748. DOI: 10.3390/biom15010116.


The Genetic Causal Effect of Autoimmune Diseases on pan-Cancers: Evidence from Mendelian Randomization.

Long Y, Pan Y, Yang H, Wang X, Jiang Z, Sun T J Cancer. 2025; 16(2):567-576.

PMID: 39744497 PMC: 11685688. DOI: 10.7150/jca.103693.